Peptides in Immunology Research

Custom Peptides are a largely untapped resource in the toils of immunology research and vaccine development

Recent advances in immunotherapy have highlighted the potential application of CAR-T cells and B-cell epitope peptide vaccines in eliciting a robust humoral polyclonal antibody response.

When compared to the more common monoclonal antibody use in cancer therapeutics, these versatile custom peptides present an often safer and cheaper alternative.

Peptides in SARS-CoV-2 Research

For infection research, peptides are combined into peptide pools with carefully selected sequences for the distinctive mutations of each SARS-CoV-2 variant. This includes the original sequence, as well as the Delta and Omicron variants

Find out more

Antibody Epitope Mapping 

PepSet™ Peptide libraries come in a myriad of formats specifically designed for antibody or T-cell receptor (TCR) epitope mapping.

One B-cell mapping strategy includes individual biotinylated peptides with overlapping sequences bound to plates. These can be screened simultaneously to quickly obtain reliable results.

For other studies, Anti-peptide antibodies can be generated with a custom synthesised peptide library. After mapping or algorithmically determining the epitopes using peptides that the entire protein sequence, selected antibodies can be generated. These generated antibodies can then be used in further assays to screen for binding and interaction sites.

Advantages of Peptides

The benefits of Mimotopes’ Peptide Libraries in immunology research are self-evident:

  • Lower cost
  • Greater availability
  • Better peptide stability
  • High affinity
  • High selectivity
  • Greater potency

Peptide tools are well-suited to the development of vaccines and immunotherapies, inhibition studies, as well as for humoral and cellular immune profiling and monitoring.

Diverse formats and modifications exist for these tools, including conjugations, peptide libraries, peptide pools, and highly purified individual deconvoluted peptides for in-depth studies. 

CONTACT US TODAY

for a peptide quote! 

☎ +61 3 9565 1111

✉ australia@mimotopes.com

☎ +1 651 603 0909

✉ useast@mimotopes.com

☎ +61 3 9565 1111

✉ asia@mimotopes.com

☎ +44 (0)151 556 0547

✉ europe@mimotopes.com

Contact us today

for a peptide quote! 

Australia

☎ +61 3 9565 1111

✉ australia@mimotopes.com

North and South America 

☎ +1 651 603 0909

 useast@mimotopes.com

✉ uswest@mimotopes.com

asia

☎ +61 3 9565 1111

✉ asia@mimotopes.com


UK / Europe / Africa / Middle East

☎ +44 (0)151 556 0547

✉ europe@mimotopes.com

Contact us today

 for a peptide quote! 

Australia

☎ +61 3 9565 1111

australia@mimotopes.com

North and South America 

☎ +1 651 603 0909

  ✉ useast@mimotopes.com 
  ✉ uswest@mimotopes.com

asia

☎ +61 3 9565 1111

✉ asia@mimotopes.com

UK/ Europe/ Africa/ Middle East

☎ +44 (0)151 556 0547

✉ europe@mimotopes.com

Go to article: Home | Improving safety for multiple drug regimes Go to article: In this issueGo to article: ContentsGo to article: Curtis Health CapsGo to article: Astrix Go to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: Covid-19 executive briefing by GlobalDataGo to article: Owen Mumford Company Insight Go to article: Owen MumfordGo to article: CommentGo to article: Use of AI in the fight against Covid-19 shows mixed results Go to article: What does Ireland’s tax hike mean for pharma?Go to article: Chinese review designations lag behind US and EUGo to article: The business benefits of text mining in life sciencesGo to article: Mettler ToledoGo to article: HOF SonderanlagenbauGo to article: In DepthGo to article: Narrow FDA panel vote on Merck’s molnupiravir bolsters outlook on mAbsGo to article: The challenges of multiple drugs safety reportingGo to article: 3D printing in drug manufacturing: unlocking future possibilitiesGo to article: Can drug repurposing uncover better treatments for UTIs?Go to article: Pfizer and Takeda deals put a spotlight on value-based pricing Go to article: Lethal injection: can pharma kill the death penalty?Go to article: Mimotopes Company Insight Go to article: MimotopesGo to article: In DataGo to article: Middle-income countries’ healthcare sectors to keep rising through to 2024Go to article: Data analytics hiring levels in clinical trial operations rose in OctoberGo to article: Industrial automation innovation in pharma rebounded in the last quarterGo to article: Global markets and indicesGo to article: Macro-economic indicatorsGo to article: Macro-economic indicators (page 2)Go to article: YearbookGo to article: SHL MedicalGo to article: Dr. Paul Lohmann Company Insight Go to article: Dr. Paul LohmannGo to article: Novo NordiskGo to article: NiproGo to article: EventsGo to article: Next issue